About Us

Learn more about the Society


The Society for Functional Precision Medicine arose out of recognition of the unmet need in matching cancer patients to the therapies best for them. We think there is tremendous utility in exposing patient tumor cells directly to the drugs that could be used to treat them in order to do this matching. We propose to bring cutting edge tools of tissue culture and analysis to bear on this strategy to create practical solutions. Our overriding mission is to accelerate the day when functional assays are a routine tool in the care of cancer patients. The SFPM welcomes the input and participation of any who are interested, including scientists and clinicians, patient advocates and regulators, academia as well as pharma and biotech.

Learn more about the SFPM in this recent podcast.

Anthony Letai, MD, PhD

Dana-Farber Cancer Institute, Harvard Medical School

Chris Kemp, PhD
Vice President

Fred Hutchinson Cancer Research Center

Keith Ligon, MD, PhD

Dana-Farber Cancer Institute, Harvard Medical School

Jeff Tyner, PhD

Oregon Health Sciences University

Diana Azzam, PhD
Board Member

Florida International University

Joan Montero, PhD
Board Member

University of Barcelona

Alice Soragni, PhD
Board Member

University of California, Los Angeles